mRNA Technology Newsletter
Issue #5October 6, 20257 studies

Protein coronas derail mRNA delivery, while new lipid designs boost organ targeting

This week brought major insights into what makes mRNA therapies work—or fail. From protein hitchhikers that hijack delivery to smart lipids that can switch between organs, researchers are cracking the code on precision gene medicine.

🎯 Protein Coronas Are Hijacking mRNA Vaccines

  • Proteins naturally coat mRNA lipid nanoparticles in the body, forming a "protein corona" that completely changes how the particles behave

  • Higher cell uptake doesn't mean better results—protein coronas actually redirect particles to cellular garbage dumps (lysosomes) instead of letting them deliver their mRNA cargo

  • Key troublemaker proteins include vitronectin, C-reactive protein, and alpha-2-macroglobulin, which consistently stick to vaccine particles

Why it matters: This explains why mRNA therapies often underperform in the body compared to lab tests—and points to new strategies for designing better vaccines.

🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Sep 30

Key Findings

🔄 One Lipid Formula Targets Three Different Organs

  • Simply changing the ratio of lipid to mRNA switches delivery between spleen (94%), liver (78%), and lung (95%) without any chemical modifications

  • Different ratios create particles with unique surface charges that attract specific "protein fingerprints" from blood

  • This approach could eliminate the need for organ-specific targeting molecules in future therapies

💡 A single versatile platform could replace multiple specialized delivery systems for different organs.
🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Oct 1

🛡️ Cancer Vaccine Reduces Inflammation Without Losing Punch

  • Engineered spleen-targeting vaccine particles maintained strong immune responses while cutting harmful inflammation

  • The approach amplified key immune cells (CD4+ and CD8+ T cells) in tumors while avoiding liver toxicity

  • Combined with checkpoint inhibitors, the vaccine significantly slowed tumor growth in mouse models

💡 Safer mRNA cancer vaccines may be possible by targeting the right organ with the right chemistry.
🥈 Top 2% journal 🔗 Theranostics Journal Article 🗓️ Oct 3

🔬 Gold Nanoparticles Create "Iterative Delivery" System

  • Co-packaging gold particles with mRNA in specialized vehicles improved tumor targeting and protein expression

  • Gold particles disable cellular traffic controllers (PP2A and Rab7), opening multiple entry pathways and helping mRNA escape cellular traps

  • The system showed enhanced therapeutic effects in solid tumor models where mRNA delivery typically fails

💡 Combining metals with genetics could overcome major barriers in cancer gene therapy.
🥈 Top 2% journal 🔗 Science advances Journal Article 🗓️ Oct 1

💊 PEG-Free Particles Avoid Immune Memory Problems

  • Alternative polymers (POEGMA, PDMA, PHPMA) successfully replaced problematic PEG components in mRNA delivery particles

  • POEGMA(+) particles showed minimal clearance issues after repeated doses, while PDMA particles resisted anti-PEG antibodies

  • This addresses a major clinical problem where repeated mRNA treatments become less effective over time

💡 Next-generation mRNA therapies may avoid the "diminishing returns" problem of current vaccines.
🎖️ Top 10% journal 🔗 Nanoscale horizons Journal Article 🗓️ Oct 1

🦠 Bivalent COVID Vaccine Outperforms Single-Target Approach

  • Vaccine targeting both Delta and Omicron BA.1 generated 87,556 neutralization titers against Delta and 52,634 against Omicron BA.1

  • Booster shots enhanced protection against newer variants BA.2.12.1 (5,701 titer) and BA.4/5 (1,290 titer)

  • The bivalent approach showed broader T-cell responses compared to Moderna's similar vaccine

💡 Multi-variant vaccines may provide more durable protection as viruses continue evolving.
Top 20% journal 🔗 Human vaccines & immunotherapeutics Journal Article 🗓️ Sep 30

⚙️ Flash NanoPrecipitation Reaches 20-Year Milestone

  • The manufacturing technology behind Pfizer-BioNTech's COVID vaccine has become the benchmark for commercial lipid nanoparticle production

  • Flash NanoPrecipitation uses rapid turbulent mixing to create consistent particles at global scale

  • The platform has expanded from research tool to enabling technology for both high-cost vaccines and low-cost antimalarial treatments

💡 A single manufacturing breakthrough has shaped both pandemic response and global medicine access.
🥈 Top 2% journal 🔗 Advanced drug delivery reviews Review 🗓️ Oct 4

Implications

These findings reveal that mRNA delivery success depends heavily on understanding and controlling protein interactions, not just the genetic payload. The convergence of organ-specific targeting, reduced toxicity, and improved manufacturing suggests we're entering a more precise era of genetic medicine.

Studies in this issue

Primary sources used for this newsletter.

  1. How protein coating on fat-based particles reduces mRNA delivery efficiency
    main storyNature communications2025-09-30PMID 41027853
  2. How water-attracting polymers affect faster removal of mRNA lipid nanoparticles after repeated doses
    key findingNanoscale horizons2025-10-01PMID 41031696
  3. Designing a vaccine that targets the spleen by separating inflammation from immune cell-driven cancer treatment
    key findingTheranostics2025-10-03PMID 41041043
  4. 20 Years of Flash NanoPrecipitation: From Precise Particle Formation to Use in Global Medicine
    key findingAdvanced drug delivery reviews2025-10-04PMID 41046104
  5. Development and testing of an mRNA vaccine targeting both Delta and Omicron COVID-19 variants
    key findingHuman vaccines & immunotherapeutics2025-09-30PMID 41025542
  6. Improving mRNA therapy by giving multiple doses
    key findingScience advances2025-10-01PMID 41032607
  7. Organ-Targeted mRNA Delivery Using a Controlled Phospholipid Polymer Carrier
    key findingACS nano2025-10-01PMID 41030181

Continue reading

All mRNA Technology issues